当前位置: 首页 >> 检索结果
5. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
作者: Nicholas D James.;Matthew R Sydes.;Noel W Clarke.;Malcolm D Mason.;David P Dearnaley.;Melissa R Spears.;Alastair W S Ritchie.;Christopher C Parker.;J Martin Russell.;Gerhardt Attard.;Johann de Bono.;William Cross.;Rob J Jones.;George Thalmann.;Claire Amos.;David Matheson.;Robin Millman.;Mymoona Alzouebi.;Sharon Beesley.;Alison J Birtle.;Susannah Brock.;Richard Cathomas.;Prabir Chakraborti.;Simon Chowdhury.;Audrey Cook.;Tony Elliott.;Joanna Gale.;Stephanie Gibbs.;John D Graham.;John Hetherington.;Robert Hughes.;Robert Laing.;Fiona McKinna.;Duncan B McLaren.;Joe M O'Sullivan.;Omi Parikh.;Clive Peedell.;Andrew Protheroe.;Angus J Robinson.;Narayanan Srihari.;Rajaguru Srinivasan.;John Staffurth.;Santhanam Sundar.;Shaun Tolan.;David Tsang.;John Wagstaff.;Mahesh K B Parmar.; .
来源: Lancet. 2016年387卷10024期1163-77页
Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone.
7. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
作者: Ian J Jacobs.;Usha Menon.;Andy Ryan.;Aleksandra Gentry-Maharaj.;Matthew Burnell.;Jatinderpal K Kalsi.;Nazar N Amso.;Sophia Apostolidou.;Elizabeth Benjamin.;Derek Cruickshank.;Danielle N Crump.;Susan K Davies.;Anne Dawnay.;Stephen Dobbs.;Gwendolen Fletcher.;Jeremy Ford.;Keith Godfrey.;Richard Gunu.;Mariam Habib.;Rachel Hallett.;Jonathan Herod.;Howard Jenkins.;Chloe Karpinskyj.;Simon Leeson.;Sara J Lewis.;William R Liston.;Alberto Lopes.;Tim Mould.;John Murdoch.;David Oram.;Dustin J Rabideau.;Karina Reynolds.;Ian Scott.;Mourad W Seif.;Aarti Sharma.;Naveena Singh.;Julie Taylor.;Fiona Warburton.;Martin Widschwendter.;Karin Williamson.;Robert Woolas.;Lesley Fallowfield.;Alistair J McGuire.;Stuart Campbell.;Mahesh Parmar.;Steven J Skates.
来源: Lancet. 2016年387卷10022期945-956页
Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5 years. We designed this trial to establish the effect of early detection by screening on ovarian cancer mortality.
8. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
作者: James C Yao.;Nicola Fazio.;Simron Singh.;Roberto Buzzoni.;Carlo Carnaghi.;Edward Wolin.;Jiri Tomasek.;Markus Raderer.;Harald Lahner.;Maurizio Voi.;Lida Bubuteishvili Pacaud.;Nicolas Rouyrre.;Carolin Sachs.;Juan W Valle.;Gianfranco Delle Fave.;Eric Van Cutsem.;Margot Tesselaar.;Yasuhiro Shimada.;Do-Youn Oh.;Jonathan Strosberg.;Matthew H Kulke.;Marianne E Pavel.; .
来源: Lancet. 2016年387卷10022期968-977页
Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population.
13. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
作者: Patricia A Ganz.;Reena S Cecchini.;Thomas B Julian.;Richard G Margolese.;Joseph P Costantino.;Laura A Vallow.;Kathy S Albain.;Patrick W Whitworth.;Mary E Cianfrocca.;Adam M Brufsky.;Howard M Gross.;Gamini S Soori.;Judith O Hopkins.;Louis Fehrenbacher.;Keren Sturtz.;Timothy F Wozniak.;Thomas E Seay.;Eleftherios P Mamounas.;Norman Wolmark.
来源: Lancet. 2016年387卷10021期857-65页
The NSABP B-35 trial compared 5 years of treatment with anastrozole versus tamoxifen for reducing subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ. This report assesses the effect of these drugs on quality of life and symptoms.
14. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
作者: Richard G Margolese.;Reena S Cecchini.;Thomas B Julian.;Patricia A Ganz.;Joseph P Costantino.;Laura A Vallow.;Kathy S Albain.;Patrick W Whitworth.;Mary E Cianfrocca.;Adam M Brufsky.;Howard M Gross.;Gamini S Soori.;Judith O Hopkins.;Louis Fehrenbacher.;Keren Sturtz.;Timothy F Wozniak.;Thomas E Seay.;Eleftherios P Mamounas.;Norman Wolmark.
来源: Lancet. 2016年387卷10021期849-56页
Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated that an aromatase inhibitor would be safer and more effective. We therefore undertook this trial to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy.
15. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
作者: John F Forbes.;Ivana Sestak.;Anthony Howell.;Bernardo Bonanni.;Nigel Bundred.;Christelle Levy.;Gunter von Minckwitz.;Wolfgang Eiermann.;Patrick Neven.;Michael Stierer.;Chris Holcombe.;Robert E Coleman.;Louise Jones.;Ian Ellis.;Jack Cuzick.; .
来源: Lancet. 2016年387卷10021期866-73页
Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS). Here, we compare the efficacy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS.
17. Does happiness itself directly affect mortality? The prospective UK Million Women Study.
作者: Bette Liu.;Sarah Floud.;Kirstin Pirie.;Jane Green.;Richard Peto.;Valerie Beral.; .
来源: Lancet. 2016年387卷10021期874-81页
Poor health can cause unhappiness and poor health increases mortality. Previous reports of reduced mortality associated with happiness could be due to the increased mortality of people who are unhappy because of their poor health. Also, unhappiness might be associated with lifestyle factors that can affect mortality. We aimed to establish whether, after allowing for the poor health and lifestyle of people who are unhappy, any robust evidence remains that happiness or related subjective measures of wellbeing directly reduce mortality.
18. A comparison of health expectancies over two decades in England: results of the Cognitive Function and Ageing Study I and II.
作者: Carol Jagger.;Fiona E Matthews.;Pia Wohland.;Tony Fouweather.;Blossom C M Stephan.;Louise Robinson.;Antony Arthur.;Carol Brayne.; .
来源: Lancet. 2016年387卷10020期779-86页
Whether rises in life expectancy are increases in good-quality years is of profound importance worldwide, with population ageing. We investigate how various health expectancies have changed in England between 1991 and 2011, with identical study design and methods in each decade.
19. Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials.
作者: Jane Wardle.;Christian von Wagner.;Ines Kralj-Hans.;Stephen P Halloran.;Samuel G Smith.;Lesley M McGregor.;Gemma Vart.;Rosemary Howe.;Julia Snowball.;Graham Handley.;Richard F Logan.;Sandra Rainbow.;Steve Smith.;Mary C Thomas.;Nicholas Counsell.;Steve Morris.;Stephen W Duffy.;Allan Hackshaw.;Sue Moss.;Wendy Atkin.;Rosalind Raine.
来源: Lancet. 2016年387卷10020期751-9页
Uptake in the national colorectal cancer screening programme in England varies by socioeconomic status. We assessed four interventions aimed at reducing this gradient, with the intention of improving the health benefits of screening.
|